The number of ACF, the number of crypts per ACF, and the number of big ACF (4 aberrant crypts per foci) were all reduced by the use of FOS and celecoxib together, indicating that FOS and celecoxib individually have not been able to promote the reduction of ACF, but jointly result in significant decrease in formation of ACF, leading to better control of colon cancer treatment and analysis. The gene discussed is FOS; the disease is colonic neoplasm.